Mineralys Therapeutics, Inc. Common Stock (MLYS) — Long-term Investment Intensity
Mineralys Therapeutics, Inc. Common Stock (MLYS) has a Long-term Investment Intensity of 1.0% as of December 2023. Long-term investments of $2.48 Million represent 1.0% of total assets of $251.64 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Explore Mineralys Therapeutics, Inc. Common Stoc operating cash flow efficiency to assess how effectively this company generates cash.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Mineralys Therapeutics, Inc. Common Stock Long-term Investment Intensity (2023–2023)
This chart shows how Mineralys Therapeutics, Inc. Common Stock's Long-term Investment Intensity has evolved across 1 annual periods from 2023 to 2023. As of December 2023, the intensity stands at 1.0%, reflecting long-term investments of $2.48 Million against total assets of $251.64 Million USD. Explore Mineralys Therapeutics, Inc. Common Stoc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Mineralys Therapeutics, Inc. Common Stock (2023–2023)
The table below presents the year-by-year Long-term Investment Intensity for Mineralys Therapeutics, Inc. Common Stock from 2023 to 2023, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see MLYS market cap.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2023 | 1.0% | $2.48 Million | $251.64 Million | — |